BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference
Rhea-AI Summary
BioAge Labs (NASDAQ: BIOA) will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 25-26, 2026. CEO Kristen Fortney will join a fireside chat on February 26 from 10:40 AM to 11:05 AM ET; management will hold one-on-one meetings.
Live webcast registration is available and replays will be archived on the company's investor website for 30 days.
Positive
- None.
Negative
- None.
News Market Reaction – BIOA
In the Feb 20 session, BIOA gained 1.84%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 11 | Earnings presentation invite | Neutral | -1.0% | Announced timing and access details for upcoming quarterly earnings presentation. |
| Feb 06 | Royalty sales update | Positive | +3.8% | Reported Leqembi Q4 2025 sales and associated royalty growth versus prior year. |
| Jan 21 | Upsized offering priced | Negative | -5.6% | Priced upsized $115M equity offering at $19.50 per share under S-3 registration. |
| Jan 20 | Proposed equity offering | Negative | +5.8% | Announced proposed public equity offering with additional underwriter option and use of proceeds. |
| Jan 20 | Clinical expansion | Positive | +5.8% | Expanded BGE‑102 into DME with planned Phase 1b/2a trial and mid‑2027 readout. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent history shows generally aligned price reactions to news, with offerings drawing pressure while clinical and commercial updates skew positive. One prior financing headline saw a positive move, indicating occasional divergence around capital-raising news.
Over the last six months, news flow included financing, clinical expansion, and partner sales data. A January 2026 clinical update on BGE‑102 and a proposed offering on Jan 20, 2026 both coincided with gains of about 5.75%, while the priced upsized offering on Jan 21, 2026 led to a 5.63% decline. Earlier royalty and scheduling updates for a related company showed moderate, mixed moves. Today’s conference appearance fits within this cadence of frequent investor‑facing communications.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- BioAge Labs, Inc. (NASDAQ: BIOA) ("BioAge", "the Company"), a clinical-stage biotechnology company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging, today announced that the Company will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference taking place February 25-26, 2026.
Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, February 26 from 10:40 AM to 11:05 AM ET. Fortney and Dov Goldstein, MD, CFO, will participate in one-on-one meetings. To access the live webcast of the presentation, register here.
Replays of the webcast will be available in the investor section of the Company's website at https://ir.bioagelabs.com/, and will be archived for 30 days following the presentations.
About BioAge Labs, Inc.
BioAge is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The Company's lead product candidate, BGE-102, is a potent, orally available, brain-penetrant small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases. A Phase 1 SAD/MAD trial of BGE-102 is underway, with topline data including additional MAD cohorts anticipated in 1H26. The Company is also developing long-acting injectable and oral small molecule APJ agonists for obesity. BioAge’s additional preclinical programs, which leverage insights from the Company’s proprietary discovery platform built on human longevity data, address key pathways involved in metabolic aging.
Contacts
PR: Chris Patil, media@bioagelabs.com
IR: Dov Goldstein, ir@bioagelabs.com
Partnering: partnering@bioagelabs.com
Web: https://bioagelabs.com
